![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
|
|||||
![]() |
Gautam
Gowrisankaran, PhD |
|
|
Biosketch: Prof. Gowrisankaran has served as a faculty member at the University of Minnesota Economics Department, and as a visiting faculty member at the Economics Departments of the University of Michigan, Harvard University and Yale University. Prof. Gowrisankaran has taught Competitive Strategy, Econometrics, Microeconomic Theory, and Industrial Organization at the undergraduate and graduate levels. Prof. Gowrisankaran has also served as a Visiting Scholar at the Federal Reserve Bank of San Francisco and as a consultant to other Federal Reserve Banks. Prof. Gowrisankaran has refereed for many economics journals, has given invited research seminars at most major economics departments in North America, and has served as a consultant or expert witness to governmental and private sector clients for a number of antitrust investigations. Abstract:We evaluate the impact of the Medicare HMO program and prescription drug coverage on elderly mortality using data from 1993 to 2000. We specify a model of plan entry and benefit choice and Medicare enrollee plan choice and health outcomes. We derive an estimator that is consistent with endogenous plan selection by using the quasi-experimental variation caused by peculiarities of the Medicare reimbursement system for HMOs. We find that enrollment in an HMO without drug coverage increases mortality while enrollment in an HMO with drug coverage has no significant impact, both relative to traditional Medicare. The economic value of the reduction in mortality from drug coverage far outweighs the costs. HMOs, and in particular HMOs without drug coverage, attract healthier enrollees than average.
|
|
Copyright ©2006 The Leonard Davis Institute of Health Economics. All Rights Reserved. |